Resolutions from CellaVision AB:s (publ), 556500-0998, Annual General Meeting (AGM) on April 23, 2008
To adopt the Statement of Income and Balance Sheet for the parent company and the Group for the year 2007.
That net profit for the year, SEK 4,433,981, be carried forward to new account.
To discharge the Board of Directors and the Chief Executive Officer from liability.
That the Board of Directors shall consist of five regular members and no alternatives.
To re-elect the following Directors: Niels Freiesleben, Christer Fåhraeus, Lars Gatenbeck, Sven-Åke Henningsson, Torbjörn Kronander
To elect Lars Gatenbeck as the Chairman of the Board.
That the remuneration to the Chairman of the Board shall amount to SEK 140,000 (140,000). The remuneration to other directors shall amount to SEK 70,000 (70,000) each, in total SEK 280,000 (280,000). Remuneration to the auditors shall be paid on a current account basis.
To approve the Board of Directors' recommendation to resolve to issue a maximum of 3,000,000 shares. If the authorization is fully implemented, there will be a maximum of 11.2 percent dilution of share capital. The General Annual Meeting's complete decisions as accounted for above are available at the company address, Ideon Science Park in Lund, and are sent to those share holders who request it.
Lund April 23, 2008
CellaVision AB (publ)
Board of Directors
CEO Yvonne Mårtensson's address to the meeting will be available in Swedish at www.cellavision.com.
For more information, please contact:
Lars Gatenbeck, Chairman of the Board, CellaVision AB. Tel: 070 535 44 44. E-mail: lars.gatenbeck@gzgroup.se
Yvonne Mårtensson, CEO, CellaVision AB. Tel: 0708 33 77 82. E-mail: yvonne.martensson@cellavision.com
About CellaVision
CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden and has subsidiaries in Jupiter, FL, USA, Toronto, ON, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.